AIM ImmunoTech

Q2 FY2026 EarningsQ2 FY2026 results missed consensus on the bottom line, with a GAAP net loss of $3.8M vs. $2.74M expected and GAAP EPS of -$0.43 vs. -$0.17 consensus. Despite the widening loss driven by a 93% YoY surge in G&A expenses, the company strengthened its balance sheet to $9.9M in cash. Strategic progress remains on track with the DURIPANC Phase 2 trial enrollment completed and pivotal Phase 3 planning initiated, with major clinical readouts expected in Q1 and Q3 2027.